Introduction
============

Globally, colorectal cancer (CRC) is the third most common cancer in men (\~746,000 cases) and the second most common in women (\~614,000 cases) as of 2012 [@B1], [@B2]. The push for precision medicine has led to a greater understanding of the molecular and genetic subtypes of CRC among the population [@B3]-[@B6], and promoted the search for prognostic and predictive biomarkers. However, while multiple molecular markers have shown promise as prognostic indicators [@B7], [@B8], attempts to utilize them in the clinic have led to conflicting results [@B9]-[@B12]. Thus, tumor stage and supporting histological analysis remain the primary basis for therapeutic decision making in CRC [@B13], [@B14].

In addition to the search for prognostic markers for CRCs, research has also focused on uncovering better drug options. Standard cytotoxic agents for CRC include 5FU, often combined with irinotecan and/or oxaliplatin [@B14]-[@B22]. In patients with advanced disease almost all patients still develop resistance to treatment and succumb to tumor growth [@B23], [@B24]. Targeted antibodies are regularly used in treating mCRC, including agents that target vascular endothelial growth factor (VEGF) and its receptor (VEGFR) [@B25]. Targeting of VEGF pathways in CRC is designed to reduce tumor blood supply by disrupting tumor vessels, and has had some success in the clinic [@B26], [@B27]. One such therapy is bevacizumab (bev; Avastin™; Genentech, San Francisco, CA), a VEGF-targeted monoclonal antibody, which has been approved for CRC patients in combination with various chemotherapy regimens. Unfortunately, most therapeutic options in CRC have faced the problem of resistance in the clinic, often due to the heterogeneous nature of colon tumors [@B27]-[@B31].

Recently, there has been a growing interest in the development of nanoparticle-based therapies, such as liposomes (LP), for cancer as multiple preclinical studies have shown notable success in cellular and animal models [@B32]-[@B38]. Clinical trials utilizing LP for CRC treatment focus primarily on delivery of well-characterized drugs, including irinotecan and its metabolite, SN-38, or doxorubicin [@B13], [@B39], [@B40]. LP deposition in solid tumors is heavily influenced by enhanced permeability and retention (EPR), making the state of tumor blood vessels a key factor in delivery. Theranostic approaches for imaging delivery of LP could provide vital insight into the probability of success when treating with LP platforms for drug delivery [@B41]-[@B43]. In this study, we have utilized a ^64^Cu-loadable liposome formulation to image the effects of short-term bev treatment on LP delivery to colon tumor xenografts in mice. We chose to target tumor vasculature, as the state of vessels in solid tumors is critical in defining EPR, and thus macromolecular delivery [@B44]-[@B46]. Although the long-term effects of bev on tumor vasculature have been established, there is evidence that bev begins altering tumor vessels and affecting vascular permeability early into treatment [@B47]. Thus, we aimed to measure any early changes in LP localization induced by short-term bev with PET, and monitor subsequent therapy with liposomal irinotecan (LP-I; MM-398; Onivyde®; Merrimack Phamaceuticals Inc., Cambridge MA). In doing so, we generated a system to measure dynamic changes in LP deposition that could affect the efficacy of LP-based therapies on an individual basis. Furthermore, we were able to non-invasively measure significant differences in LP delivery between bev-treated tumors and control tumors early into bev treatment. Finally, the results seen with PET correlated with subsequent monitoring of treatment efficacies, suggesting that this platform could have utility in predicting and monitoring therapeutic LP success.

Materials and Methods
=====================

Materials
---------

HT-29 cells and McCoy\'s 5a Modified Medium were purchased from ATCC (Manassas, VA) and kept below 15 passages following receipt. 4-DEAP-ATSC chelator, empty MM-DX-929 liposomes, and LP-I were provided by Merrimack Pharmaceuticals, Inc. (Cambridge, MA). ^64^CuCl~2~ was purchased from the Department of Radiology at Washington University (St. Louis, MO). Chelation efficiency was measured with iTLC-SG plates (Agilent Technologies, Santa Clara, CA). Loading efficiency was assessed with Sephadex G-50 DNA Grade Illustra Nick columns (GE Healthcare, Pittsburg, PA).

Gamma spectroscopy was performed on a Packard Cobra II gamma counter (Perkin-Elmer Inc., Waltham, MA). PET scans were acquired on an R4 microPET (Concorde Microsystems, Knoxville, TN). CT images were acquired using an Inveon microSPECT/CT (Siemens Preclinical Imaging Solutions, Malvern, PA). Images were registered and analyzed using PMOD Image Matching and Fusion Tool ver3.6 (PMOD group, Switzerland). Statistical analyses were performed using GraphPad Prism, v7 (GraphPad Software Inc., La Jolla, CA).

Labeling MM-DX-929 with chelated ^64^Cu
---------------------------------------

Upon receipt of ^64^CuCl~2~, ^64^Cu was chelated with 4-DEAP-ATSC (98±2% chelation efficiency), followed by loading into empty liposome (95±3% loading efficiency). Briefly, ^64^CuCl~2~ was vortexed with 4-DEAP-ATSC solution (0.06 mg/mL chelator in 0.1 M citrate buffer, pH 6) at room temperature for 10 s, then allowed to sit for one minute and vortexed again. Efficiency of ^64^Cu chelation was determined by diluting a sample in citrate buffer for instant thin layer chromatography as described previously [@B48]. Briefly, radioactivity of the solvent front (free ^64^Cu in solution) and at the sample origin (^64^Cu-DEAP-ATSC complex) was measured by gamma spectroscopy of the iTLC plates. Greater than 90% chelation efficiency was required to proceed to loading.

^64^Cu-MM-DX-929 was prepared by mixing ^64^Cu-DEAP-ATSC with empty MM-DX-929 liposomes (15mM phospholipid in 10 mM HEPES buffered saline, 150 mM sodium chloride, pH 6.5) and heated for 10 min at 65**°**C, followed by immediate cooling in an ice water bath for 1 min, as previously described [@B48]. Loading efficiency of ^64^Cu was assessed by performing size exclusion chromatography on an Illustra NICK column with a small sample of prepared ^64^Cu-MM-DX-929 in HEPES buffered saline (HBS). Radioactivity of the eluent containing labeled ^64^Cu-MM-DX-929 in HBS, and the column containing ^64^Cu-DEAP-ATSC was measured with gamma scintigraphy. Greater than 90% labeling efficiency was achieved before proceeding with animal imaging.

Cell Culture
------------

HT-29 human colorectal adenocarcinoma cells were cultured in McCoy\'s 5a Modified Medium supplemented with 5% fetal bovine serum and 1% penicillin/streptomycin, as described by ATCC. Cells were kept at 37°C with 5% CO~2~ and were passaged with trypsin at approximately 80% confluence. Prior to inoculation in mice, cells were not passaged more than ten times in culture. Cell line identity was authenticated at time of all studies with the PowerPlex® 16 System from Promega (Madison, WI) in the Applied Genomics Technology Center at Wayne State University. Analyses were performed using ATCC and DSMZ reported karyotypes.

Animal Studies
--------------

### Tumor model

Cultured HT-29 human colorectal adenocarcinoma cells were used to establish a subcutaneous tumor model in female SCID NCr mice (Charles River Labs; MA) and thereafter maintained in serial passage.

### MicroPET studies

Schematic representation of mouse study design is presented in Figure [1](#F1){ref-type="fig"}. Tumor fragments were subcutaneously implanted into SCID NCr female mice on day 0 by trochar. Tumors were upstaged to 250 mg (range: 200-300 mg, day 12), and mice were non-selectively randomized into their respective control (No Rx) and treatment groups (bev). All mice were imaged with microPET before and after bev treatment (on days 13 and 20) 24 h after IV administration of ^64^CuCl~2~ MM-DX-929. Scans were compared for changes in LP accumulation during this time period. Mice were euthanized under anesthesia with whole blood and tissues collected after the second PET for biodistribution measurements and histological analysis. For subsequent studies, after the 2^nd^ scan, mice were further divided into 4 groups of n=6 (No Rx, Bev, LP-I, and Bev + LP-I) to assess tumor progression post bev treatment, with or without LP-I, compared to untreated controls. All mice were weighed and observed daily for the duration of the study. Tumors were measured by caliper 2-3x/week with the formula \[volume (mg) = length (mm) x width^2^ (mm^2^)/2\] used to calculate tumor mass.

### Tracer preparation and injection

Empty LP MM-DX-929 (Merrimack Pharmaceuticals, Cambridge, MA) were labeled with ^64^CuCl~2~ chelated with 4-DEAP-ATSC). Mice were administered 200-300 μCi/injection intravenously (IV) within a 0.1-0.3 mL volume range; 22-24 h prior to each microPET scan.

### Drug preparation

Bevacizumab was prepped fresh for each injection from 25 mg/mL stock diluted with 0.9% sterile saline, pH 6.0 and injected intraperitoneally (IP) at 5 mg/kg in a volume of 0.2 mL/20g mouse on days 14 and 17.

Liposomal Irinotecan (LP-I; MM-398; Onivyde^®^, Merrimack, Cambridge, MA) was prepped fresh for each injection from 5.05 mg/mL stock diluted with 0.9% sterile saline, pH 6.0 and injected IV at 10 mg/kg in a volume of 0.2 mL/20g mouse on days 21, 24, and 28.

All animal studies were approved by and performed in strict accordance with the policies of the Institutional Animal Care and Use Committee (IACUC) at Wayne State University.

Animal Imaging with ^64^Cu-MM-DX-929 PET
----------------------------------------

^64^Cu-MM-DX-929 (104 nm) was used to approximate the systemic distribution of LP-I (110 nm), as it has been shown to predict the accumulation of LP-I in solid tumors (Helen Lee, Personal communication). Following ^64^Cu-liposome preparation, mice received approximately 200-300 µCi of ^64^Cu-MM-DX-929 (20 μmol/kg lipid) intravenously via the tail vein. ^64^Cu-MM-DX-929 was imaged with PET 24±2 h post-injection, as liposomes remain in the blood pool for extended periods before depositing in tissues. Anesthesia was induced with 3% inhaled isoflurane, and maintained during scanning with 2% isoflurane. Mice were positioned prone on the scanner bed with heating pad to maintain body temperature. Fiducials labeled with ^64^Cu were fixed to the bed for subsequent alignment of PET and CT images. PET acquisition was performed for 10 min, followed by CT scanning for 10 min to obtain anatomical images.

Attenuation correction was performed on the whole body microPET images based on previously recorded transmission scans. Images were reconstructed by applying an iterative ordered-subsets expectation maximization 2-dimensional algorithm [@B49]. Together with scatter correction, these parameters yielded an isotropic spatial resolution of approximately 2 mm in full width at half maximum [@B50]. Prior to study, a phantom for ^64^Cu was scanned to calculate conversion from counts/pixel/min to kBq(μCi)/cm^3^.

PET/CT image registration and analysis
--------------------------------------

PET and CT images were registered and aligned using the PMOD Image Matching and Fusion Tool ver3.6 (PMOD group, Switzerland). Regions of interest (ROIs) were defined manually on individual planes of the PET, using the aligned CT images for anatomical reference. 3-dimensional volumes of interest (VOIs) were generated from the stacked ROIs of the tissue of interest. Activity in the VOIs, as detected by PET in kBq(μCi)/cm^3^, was converted to standardized uptake values based on injected dose and body weight. SUV~max~ values were calculated by averaging the max pixel value in the ROI of the three hottest consecutive planes in a tissue, and normalizing to injected dose and body weight.

^64^Cu-MM-DX-929 PET imaging of short-term bev effects
------------------------------------------------------

A baseline ^64^Cu-MM-DX-929 PET was performed on all mice at day 14 post-tumor implant, followed by half of the mice receiving 2 injections of bev over 7 days. Bev was administered IP at 5 mg/kg in a single injection performed on days 14 and 17 (two total injections). All mice received a second ^64^Cu-MM-DX-929 PET on day 20. Day 20 scans (post-treatment) were compared to scans from day 13 (baseline) and analyzed for changes in ^64^Cu-MM-DX-929 delivery to tumor. Results were compared between bev-treated and control mice.

Whole body tissue distribution of ^64^Cu-MM-DX-929
--------------------------------------------------

^64^Cu-MM-DX-929 retention in bulk tissues was assessed by gamma spectroscopy of resected tissues. Briefly, following the second PET scan (day 7), mice were sacrificed and tissues harvested (n=8). These included tumor, liver, heart, lung, intestine, stomach, kidney, spleen, and blood. Tissues were washed, weighed, and activity was measured for 1 min on a gamma counter. Activity in tissues was corrected for decay and normalized to tissue weight (kBq/cm^3^). Tissue biodistribution was compared between bev-treated and untreated mice to ensure that bev treatment was not affecting retention of ^64^Cu-MM-DX-929 in healthy tissues.

Immunohistochemistry and microvessel density analysis
-----------------------------------------------------

Tumors resected after the second PET were fixed in formalin and paraffin embedded. Immunohistochemistry for CD34, and staining with hematoxylin (Sigma Aldrich, St. Louis, MO) was performed on 5 µm slices, and digital images of the entire cross section were captured. Sample identities were blinded, and images were analyzed with Pannoramic Viewer v1.15.4 (3DHISTECH Ltd., Budapest, Hungary). For each tissue, five distinct areas of 200 mm^2^ were utilized in assessing microvessel density. Briefly, tumor blood vessels (as identified by CD34 staining) were counted in each section, and distance measurements across the widest diameter of each vessel were used to determine vessel size. The average number of vessels per cm^3^ and the average vessel diameter were calculated.

Statistical Analysis
--------------------

Tumor growth curves with mean ± standard error were plotted and growth rates were tested with linear mixed model. Tumor latency to 1 g total burden was tested with Kruskal-Wallis test, after normality assumption was evaluated with Shapiro-Wilk test. Statistical analyses were performed using R v3.2 (The R Foundation for Statistical Computing). All other statistical analyses were performed using GraphPad Prism 7 (GraphPad Software Inc., La Jolla, CA). Data were presented as the mean ± standard error. Comparisons between the bevacizumab and control were performed using two-sample Student\'s t-test. A p-value of \<0.05 was considered statistically significant.

Results
=======

^64^Cu-MM-DX-929 PET can detect significant differences in LP delivery between colon tumors treated with bev and untreated controls
-----------------------------------------------------------------------------------------------------------------------------------

Liposome distribution in mice bearing subcutaneous HT-29 colon tumor xenografts was measured with ^64^Cu-MM-DX-929 PET at baseline prior to any treatment. Due to the extended circulation times of liposomes in the body, images were acquired 24±2 h following tracer injection (approximately two half-lives of ^64^Cu, t~1/2~ = 12.7 h) to allow extravasation from the blood pool [@B48]. Tracer uptake was notable in liver (due to extensive vasculature) and spleen, and was still visible in the heart (residual blood pool). Tumors were easily detectable with ^64^Cu-MM-DX-929 PET, with relatively ubiquitous tracer distribution at baseline.

By measuring changes in tumor SUV~max~ between baseline and post-treatment scans (%ΔSUV~max~) we found the difference in %ΔSUV~max~ of bev-treated tumors compared with the controls to be statistically significant (Figure [2](#F2){ref-type="fig"}). This trend was seen when comparing mice (2 tumors/mouse), but was also true when comparing individual tumors (Figure [S1](#SM0){ref-type="supplementary-material"}). Scans from two control mice were determined to be un-evaluable due to technical issues with one or both PET images for those mice. Changes in ^64^Cu-MM-DX-929 PET from baseline to post-treatment were noticeably different between tumors treated with bev and untreated controls. Tumors in control mice showed relative increases in ^64^Cu-MM-DX-929 retention after 7 days (Figure [3](#F3){ref-type="fig"}). Although these tumors often continued to grow between baseline and subsequent scans, increases in ^64^Cu-MM-DX-929 deposition was independent of individual tumor size or growth rate (data not shown). In mice treated with bev, however, ^64^Cu-MM-DX-929 delivery to tumor tissues appeared to remain stable between baseline and post-treatment scans (Figure [4](#F4){ref-type="fig"}). Again, these trends were independent of tumor size or growth rate (data not shown).

Interestingly, ^64^Cu-MM-DX-929 PET scans visualized more frequent and dramatic shifts in the volumetric distribution of tracer across the mass of tumors treated with bev. This suggests that early into treatment, prior to measurable morphological differences, ^64^Cu-MM-DX-929 PET identified altered tumor vascularity in bev-treated tumors, as well as early effects of bev on LP distribution. ^64^Cu-MM-DX-929 PET images suggest that the early effects of bev may substantially alter or limit LP penetration into tumor tissues. Additionally, changes in tracer deposition in individual tumors were more highly variable in bev-treated tumors, while control tumors often exhibited similar increases in uptake over time (Figure [S2](#SM0){ref-type="supplementary-material"}). Taken together, ^64^Cu-MM-DX-929 PET was able to detect increased LP accumulation/delivery in colon tumor xenografts tended to increase as tumors progressed without intervention, but this trend was reduced or abolished with only two doses of bev. Thus, with ^64^Cu-MM-DX-929 PET we were able to measure the effects of bev therapy on LP delivery to solid tumors early into treatment.

Bevacizumab does not alter systemic distribution of ^64^Cu-MM-DX-929 in non-tumor tissues
-----------------------------------------------------------------------------------------

Any treatment with the potential to alter systemic distribution of a PET tracer could confound image analysis and uptake quantitation. To verify that bev did not significantly alter ^64^Cu-MM-DX-929 global uptake in tissues, activity in resected normal tissues was measure by gamma spectroscopy and compared between treated and untreated mice. No significant differences were detected between normal tissues of bev-treated mice and control mice (Figure [5](#F5){ref-type="fig"}). This demonstrates that systemic distribution was not altered in a way which would be confounding for image analysis in tissues of interest.

Colon tumor growth was delayed by short-term bev alone, liposomal irinotecan alone, or short-term bev followed by liposomal irinotecan
--------------------------------------------------------------------------------------------------------------------------------------

Following the second ^64^Cu-MM-DX-929 PET, bev-treated mice and untreated mice were further randomized into the following subsets: (1) untreated controls (n=6); (2) short-term bev (2q7d) only (n=6); (3) LP-I only (n=6); (4) short-term bev followed by LP-I (n=6) (Figure [1](#F1){ref-type="fig"}). One mouse assigned to receive LP-I only (group 3) was not included in data assessments due to lack of drug availability at the time of study. Mice were treated and tumor progression was monitored until tumor burden or weight loss warranted euthanasia. Tumor growth was considered individually, as well as by per-mouse analysis of total tumor burden.

As expected, HT-29 tumors in mice that received no treatment exhibited unrestrained growth (Figure [6](#F6){ref-type="fig"}A). Treatment with two doses of bev resulted in a measurable but modest delay in tumor progression compared to controls. Interestingly, tumors in mice treated with LP-I also exhibited delayed growth compared to controls, despite being administered later than bev, at advanced stage of disease. Succeeding short-term bev with LP-I demonstrated tumor inhibition compared to untreated controls, although there was no notable therapeutic advantage to this combination compared to bev or liposomal irinotecan alone with the specific doses and regimens tested.

As was seen in the PET scans with bev, individual tumor and mouse responses varied in each of the treatment groups. Spaghetti plots of tumor burden in individual mice show that while untreated tumors progressed similarly quickly, each treatment regimen yielded variable rates of response in individuals (Figure [6](#F6){ref-type="fig"}Ca-d). Tumor growth rates and drug-induced growth inhibition were independent of tumor size at treatment initiation (data not shown). When measuring tumor latency to 1 g total burden per mouse, each treatment group shows increased latency compared to untreated controls, though the differences in group medians were not statistically significant (Figure [6](#F6){ref-type="fig"}B).

Bev treatment induced measurable changes in tumor blood vessels after two injections
------------------------------------------------------------------------------------

Although treated mice received only two injections of bev, HT-29 tumors resected after the second ^64^Cu-MM-DX-929/PET showed early evidence of bev action. Microvessel density (MVD) was assessed via immunohistochemical staining for CD34, followed by blinded analysis of tissues for vessel number and average diameter. CD34 staining revealed notable differences in vessel size between bev-treated and control tumors (Figure [7](#F7){ref-type="fig"}A). Short-term bev resulted in significantly smaller vessel diameters compared to untreated controls (Figure [7](#F7){ref-type="fig"}B). The total tissue area occupied by CD34+ vessels in treated tumors was 3.8% ± 1.5% compared to 5.7% ± 1.7% in control tumors (p=0.04, Figure [S3](#SM0){ref-type="supplementary-material"}). This indicates that ^64^Cu-MM-DX-929 in the blood pool has a very small contribution to the tumor tracer activity. While the size of the vessels was noticeably altered following bev, the vessel density (vessels/cm^3^) showed no measurable difference between bev-treated and untreated tumors (Figure [7](#F7){ref-type="fig"}C). These data would indicate that two injections of bev had begun eliciting an anti-vascular effect, and that the second ^64^Cu-MM-DX-929 PET was performed during the early stages of bev response. Taken together with trends seen in PET, these data show that ^64^Cu-MM-DX-929 PET was able to measure changes in LP delivery, which were likely due to the early effects of bev. Importantly, while bev-induced changes in vessel diameter were measurable at the time of the second PET, no difference was seen in tumor growth rates between treated and control mice (Figure [6](#F6){ref-type="fig"}A). Thus, ^64^Cu-MM-DX-929 PET was able to measure early fluctuations in LP delivery due to anti-vascular therapy, prior to any quantifiable changes to tumor morphology.

Discussion
==========

The urgent need for precision medicine for CRC is not limited to the development of more sophisticated therapies, but also techniques to predict and monitor therapeutic efficacy. Here we have demonstrated the utility of a dynamic system using ^64^Cu-labeled liposomes for PET to non-invasively measure the early effects of bev therapy on LP delivery to colon tumor xenografts in mice. Furthermore, significant differences measured with ^64^Cu-MM-DX-929 PET between bev-treated and control tumors provided early insight into therapeutic outcomes in mice subsequently treated with liposomal irinotecan.

Clinically, the potential advantages of LP are twofold: (1) sustained and/or local delivery of drugs or drug combinations to tumor tissues, and (2) reduced toxicity profiles as normal tissues are shielded from toxic drugs [@B51]-[@B55]. However, heterogeneous, inconsistent, or obstructed delivery of these nanoparticles to tumor tissues can hamper their effectiveness, and is hypothesized to be a contributor to the lack of clinical success seen with many LP. Passive targeting through EPR relies on specific properties of tumor blood vessels, which are constantly changing in response to the tumor environment and therapeutic intervention, particularly with antivascular agents. While antivascular agents are expected to disrupt tumor vessels, there is some evidence suggesting that early effects of bev treatment may transiently "normalize" tumor vessels, though these effects are not consistent [@B47], [@B56]-[@B58]. Thus, a non-invasive means of measuring LP delivery to tumor tissues could provide individualized information on the effect of drugs like bev on LP delivery and subsequent efficacy [@B48], [@B59]-[@B61].

In these studies, we found that we could use PET to quantify changes in LP accumulation in colon tumor xenografts very early into bev treatment. In mice that received no treatment in between PET scans, ^64^Cu-MM-DX-929 accumulation in tumors increased, indicating that LP-I were still able to reach and penetrate HT-29 tumor tissues and elicit an effect. While previous studies of LP-I in HT-29 tumors demonstrated significant anti-tumor effects when administered earlier into tumor progression [@B62], [@B63], the modest effects seen here were likely attributed to treatment initiation at late-stage disease. Because of this, we anticipated no significant difference in survival among the treatment groups. After two injections over the course of one week, bev had already begun eliciting anti-vascular effects, which were quantifiable with ^64^Cu-MM-DX-929 PET. While bev treatment conferred therapeutic advantage in HT-29 tumors, ^64^Cu-MM-DX-929 PET showed that even short-term bev treatment began to impede liposome delivery and penetration. This observation is consistent with the lack of therapeutic benefit seen in treating mice with LP-I that had already received bev.

In the clinic, bev and other antivascular agents, such as ziv-aflibercept (Zaltrap®; Regenron Pharmaceuticals Inc., Tarrytown, NY), are approved to treat patients with CRC. As liposome-based therapies are introduced for this population, understanding the effects of antivascular agents on LP delivery could reduce the probability of employing incompatible drug combinations. Furthermore, when designing clinical trials of LP-drug platforms for colon cancer, imaging techniques could be used to non-invasively monitor changes in LP delivery over time, or as a result of various therapies.

Along with the clinical implications of bev and LP-therapy in CRC patients, we have been able to employ a powerful model for dynamically assessing modulation of LP delivery. ^64^Cu-MM-DX-929 PET was able to non-invasively quantify the effects of bev on LP delivery, which likely affected subsequent therapy with liposomal irinotecan injection. This would suggest that ^64^Cu-MM-DX-929 PET may be sensitive enough to detect and monitor changes in LP delivery to solid tumors, which may directly influence therapeutic LP efficacy. Aspects of the tumor environment that affect LP distribution are dynamic, and are certain to vary among patient populations. Thus, predicting and monitoring LP delivery with non-invasive theranostic imaging is an invaluable tool in achieving precision medicine with LP for CRC patients.

Finally, the mission of individualized treatment plans for patients with cancer is one that requires a significant preclinical effort to identify diagnostic and therapeutic strategies. In this study, we have demonstrated a practical system for measuring therapeutic modulation of LP delivery that predicted and described subsequent therapeutic results. ^64^Cu-MM-DX-929 PET may be used in preclinical studies of therapeutic LP to efficiently measure the effect of combination therapies, treatment timelines/conditions, etc. on LP delivery. Utilizing imaging protocols with tracer LP like ^64^Cu-MM-DX-929 can quickly and non-invasively identify treatment conditions that improve or hinder LP delivery. In CRC, this could mean creating more avenues towards precision medicine with liposomes to improve outcomes for patients.
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![**Animal study design.** Schematic representation of treatment groups and timeline for mice treated with bev, LP-I, bev followed by LP-I, and controls.](thnov07p4229g001){#F1}

![**Changes in SUV~max~ of HT-29 colon tumors decreased after treatment with bev compared to untreated tumors.** %ΔSUV~max~ of liposome accumulation in tumor tissues of mice that received no treatment (n=10), compared to mice treated with two doses of bev (n=12) as measured by ^64^Cu-MM-DX-929 PET. %ΔSUV~max~ values represent the average %ΔSUV~max~ of both tumors within an individual mouse. (*\*\*\*p=0.0002*)](thnov07p4229g002){#F2}

![**^64^Cu-MM-DX-929 delivery to HT-29 colon tumor xenografts increases after 7 days without therapeutic intervention.** ^64^Cu-MM-DX-929 scans of a mouse bearing two subcutaneous HT-29 colon xenografts (outlined) at baseline (A) and after 7 days with no treatment (B). Images are coronal slices of the mouse midsection with fused PET/CT, PET alone, and CT alone. PET images were scaled from ½ background (kBq/cm^3^) to liver average (kBq/cm^3^) calculated based on average values from both scans.](thnov07p4229g003){#F3}

![**^64^Cu-MM-DX-929 delivery to HT-29 colon tumor xenografts does not increase when treated with two doses of bevacizumab.** ^64^Cu-MM-DX-929 scans of a mouse bearing two subcutaneous HT-29 colon xenografts (outlined) at baseline (A) and after 7 days of bev treatment (B). Images are coronal slices of the mouse midsection with fused PET/CT, PET alone, and CT alone. PET images were scaled from ½ background (kBq/cm^3^) to liver average (kBq/cm^3^) calculated based on average values from both scans.](thnov07p4229g004){#F4}

![**Bev treatment did not change overall biodistribution of ^64^Cu-MM-DX-929.** %injected radioactive dose per g of resected tissues was measured directly after the second ^64^Cu-MM-DX-929 PET scan.](thnov07p4229g005){#F5}

![**HT-29 tumor growth is affected by bev, LP-I, and bev followed by LP-I compared to untreated controls.** Tumor growth inhibition assessed by caliper measurements represented for each treatment group compared to control, represented as a mixed linear model (\*\*\*\*p\<0.0001) (A). Tumor latency to approximately 1 g total tumor burden was assessed for individual mice as a measure of growth delay due to treatment (B). Spaghetti plots of tumor growth in individual mice according to treatment with bev (C.b), LP-I (C.c), or bev followed by LP-I (C.d) compared to control tumors (C.a). Bev administration is indicated by red lines, LP-I administration is indicated by blue lines.](thnov07p4229g006){#F6}

![**Bev induced significant changes in blood vessel diameter early into treatment.** 20x images of HT-29 tumor tissues stained with CD34 to identify blood vessels (brown) and hematoxylin to denote cell nuclei (blue) show significant differences in vessel size between untreated controls (A. a-c) and tumors treated with bevacizumab (A. d-f). Microvessel density analysis of blood vessel diameter in bev-treated tumors compared to untreated controls (B). Vessel density (vessels per cm^3^) was compared between treated and untreated tumors (C). Data are presented as mean ± SD. \*\*p=0.0042](thnov07p4229g007){#F7}
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